About Us
Technology & Pipeline
Governance
Investors
Media
Contact

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Financial Reports and Presentations

2007

2017
2016
2015
2014
2012
2011
2010
2009
All years

Other

Interim reports
Annual reports
Presentations
Other
All types

	Report
September 10, 2007Communiqué from Annual General Meeting 2007-09-10

Share this page

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com